CD147 Plasma Levels in Hospitalised Patients with Covid-19 Pneumonia Predict Illness Severity and In-Hospital Mortality.
David M SmadjaAurélien PhilippeEloara V M FerreiraRudolf K F OliveiraColm McCabeLan ZhaoPublished in: Stem cell reviews and reports (2023)
COVID-19 and infectious diseases have been included in strategic development goals (SDG) of United Nations (UN). The CD147 receptor is one of several receptors for the SARS-CoV-2 spike protein that could mediate Covid-19 viral infection of host cells. It has been recently proposed to regulate viral invasion and dissemination among lymphocytes and progenitor/stem cells. A soluble by-product of CD147 (sCD147) exists in plasma and has been previously identified as a marker of diabetes and platelet activation. We examined plasma sCD147 levels in 161 Covid-19 patients at hospital admission. We demonstrated significantly higher plasma sCD147 levels in Covid-19 patients, which correlated with plasma multiorgan dysfunction biomarkers interleukin-6, creatinine and Troponin I. Importantly, sCD147 admission levels were associated with Covid-19 severity and survival, carrying potential value as a biomarker in hospitalized patients with Covid-19 infection.
Keyphrases
- sars cov
- coronavirus disease
- respiratory syndrome coronavirus
- stem cells
- infectious diseases
- emergency department
- type diabetes
- healthcare
- induced apoptosis
- cardiovascular disease
- oxidative stress
- adipose tissue
- cell death
- cell cycle arrest
- insulin resistance
- protein protein
- bone marrow
- human health
- global health
- pi k akt
- mechanical ventilation
- community acquired pneumonia